Vaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lucaccioni Héloïse, Pozo Francisco, Pérez-Gimeno Gloria, Dürrwald Ralf, Uras Marina, Domegan Lisa, Oroszi Beatrix, Meijer Adam, Trobajo-Sanmartín Camino, Ujvari Dorina, Rodrigues Ana Paula, Mlinarić Ivan, Lazar Mihaela, Rivas Wagner Eva, Erdwiens Annika, Enouf Vincent, McKenna Adele, Túri Gergő, de Lange Marit, Martínez-Baz Iván, Latorre-Margalef Neus, Guiomar Raquel, Kurečić Filipovic Sanja, Dinu Sorin, Mokoroa Olatz, Tolksdorf Kristin, Masse Shirley, Bennett Charlene, Kristóf Katalin, Hooiveld Mariette, Castilla Jesús, Santos João, Višekruna Vučina Vesna, Popescu Rodica, Bacci Sabrina, Kaczmarek Marlena, Kissling Esther
Аннотация
RESEARCH DESIGN AND METHODS: Specimens were collected from patients with acute respiratory infection. All or a random sample of viruses were sequenced. VE was (1-odds ratio) × 100, adjusted for confounders.
RESULTS: We included 7275 cases and 17,516 controls (weeks 40-2024-18-2025). The overall VE was 46% (95% CI: 40-52), lowest in adults ≥65 years at 28% (95% CI: 12-42). VE against influenza A(H1N1)pdm09 was 30% (95% CI: 19-40); ranging 16-34% by age and vaccination target group. Most (88%) circulating clades were 5a.2a, distinct from the vaccine clade. VE was 28% (95% CI: 7-45) against 5a.2a (C.1.9), and 6% (95% CI: -62-45) against the vaccine-matched clade 5a.2a.1 (D). VE against influenza A(H3N2) was 38% (95% CI: 26-49); ranging 20-66% by age and target group. Circulating viruses belonged to the vaccine clade 2a.3a.1, with 88% subclade (J.2). VE against influenza B was 76% (95% CI: 69-81); ranging 70-80% by age and target group; all viruses belonged to the vaccine clade V1A.3a.2, with diverse subclades.
CONCLUSIONS: Influenza vaccination protected approximately one in two vaccinated individuals against medically attended infection in primary care in Europe, 2024/25, varying by (sub)type and age.